Comparative Pharmacology
Head-to-head clinical analysis: MYCHEL S versus NEO FRADIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCHEL S versus NEO FRADIN.
MYCHEL-S vs NEO-FRADIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. It also disrupts bacterial cell membrane integrity.
200 mg orally every 12 hours for 14 days
50-100 mg/kg/day orally in 3-4 divided doses. Maximum 3 g/day.
None Documented
None Documented
3-4 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
2-3 hours in normal renal function; prolonged to 24-30 hours in anuria or severe renal impairment; no significant change in hepatic disease.
Renal: 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal: >90% unchanged drug via glomerular filtration, with small amount reabsorbed; biliary/fecal: <2%.
Category C
Category C
Antibiotic
Antibiotic